Navigation Links
Gut research yields new anti-cancer approach

Researchers believe they have discovered by chance a new way to fight colorectal cancer, and potentially cancers of the esophagus, liver and skin. Early work shows that a group of compounds called peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibitors may have an unexpected cancer-fighting effect, according to research published today in the journal International Cancer Research. Furthermore, the new studies suggest that PPARgamma inhibitors act through some of the same mechanisms as the blockbuster chemotherapy Taxol, but with key differences.

While studying whether compounds known to affect PPARgamma could play a role in inflammatory bowel diseases, a team at the University of Rochester Medical Center found that medium-to-high doses of PPARgamma inhibitor killed colorectal cancer cell lines. Despite the compound's class name, the anti-cancer effect has nothing to do with the ability of the compounds to inhibit PPARgamma function. Researchers believe that PPARgamma inhibitors instead attack the "skeletons" of cancer cells that enable them to reproduce, grow and spread. Better solutions are needed because, according to the American Cancer Society, colorectal cancer remains the no. 2 cause of cancer death for men, and the no. 3 cause of cancer death for women.

"This is the first observation of a small molecule dramatically reducing levels of the proteins called tubulins, the building blocks of cancer cell skeletons," said Katherine L. Schaefer, Ph.D., a research assistant professor within the Department of Medicine, Gastroenterology and Hepatology Division, at the University of Rochester Medical Center, and first author of the paper. "Because cells that line the colon are similar to those in the liver, esophagus and skin, we see potential for a new way to treat those cancers as well."

In the study that led to the discovery of the anti-cancer effect, researchers were looking for new ways to reduce inflammation seen in Crohn'
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gut research yields new anti cancer approach

(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... in the United States National Museum of Natural History ... Insects, researchers have found 16 new species of wasps ... species. The new species are described and illustrated ... a Key of the Charipinae (Hymenoptera: Cynipoidea: Figitidae) From ...
... recommendations is weak among people suffering from metabolic syndrome ... the Nordic SYSDIET study led by the University of ... high in salt and saturated fat, and too low ... have a sufficient intake of vitamin D. Metabolic syndrome ...
... can cause functional inhibition of remote regions such ... diaschisis. This phenomenon is often analyzed using positron ... these methods are expensive and radioactive. Dr. Yunjun ... Wenzhou Medical University in China quantified the changes ...
Cached Biology News:Nordic study: Few persons with metabolic syndrome adhere to nutrition recommendations 2
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 As a ... often required by our pharmaceutical manufacturing clients, Whitehouse Laboratories ... sponsorship of the Berkenstock Race Team for the 2015 ... not only speed, but a strong sense of precision ... that lead to success in the quality control testing ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... -Company,s New Name is PROLOR Biotech, Inc.- , , ... -Shareholders Approve Re-Election of Board of Directors and Other Proposals- ... (OTC Bulletin Board: MODG) today announced that shareholders approved a ... at its Annual Meeting of Shareholders held on May 21, ...
... sale in the United Statesfor treatment of pain and fever ... Cumberland Pharmaceuticals ( www.cumberlandpharma.com ) today announced ... Caldolor(TM) , an intravenous formulation of ibuprofen, through a priority ... for sale in the United States for the treatment of ...
... SEATTLE, June 11 ... results of a,large-scale Phase III study of Circadin(R) ... efficacy and safety in elderly patients.,The results were ... SLEEP,2009, the 23rd Annual Meeting of the Associated ...
Cached Biology Technology:Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 3Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients 2